BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the inauguration of its small-molecule innovative drug global industrialization base in Suzhou, Jiangsu province. The 50,000 square meter facility is projected to produce 1 billion tablets/granules of solid preparations annually.
State-of-the-Art Production Capabilities
The plant is equipped with commercial-scale and flexible production capabilities for clinical medications. It is designed to swiftly translate high-quality research and development outcomes from both large and small molecule pipelines from the laboratory to clinical product production, and subsequently to commercial production. This new facility will provide production support for BeiGene’s expanding product pipeline, which includes small and medium-sized molecule commercial drugs and large and small molecule clinical candidate drugs.- Flcube.com
